BIO 2026: How NIH cuts have threatened US competitiveness against China
Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.
Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.
Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential